COVID-19 – A semi-synthetic vaccine in the preclinical phase

Glycovax Pharma

Glycovax Pharma, a biopharmaceutical company based at Montreal, is actively working on the development of a new vaccine approach to counter COVID-19. The prototype glycoconjugate vaccine is currently in the preclinical phase.

Pr. René Roy, world expert in glycochemistry

Since the start of the COVID-19 pandemic, the team of researchers and scientists at Glycovax Pharma, led by Pr. René Roy, world expert in glycochemistry, member of NanoQAM, has analyzed the specific biomarkers of this virus. This research made it possible in particular to discover that several biomarkers identified on the virus are part of the library of glycoconjugate immunogens developed in the context of the work of researchers at Glycovax Pharma. In addition, the structures of these carbohydrates are very similar to the structures on which the company has focused its work since 2017.

Read the article: Glycovax Pharma